Explore / Clinical trial
Clinical trial

Effect of Ketanserin After LSD Administration

University Hospital, Basel, SwitzerlandCompletedPhase 1Started Oct 16, 202024 enrolledSwitzerlandNCT04558294

Abstract

LSD (lysergic acid diethylamide) is a serotonergic (5-HT) hallucinogen widely used for recreational and/or ethnomedical purposes. LSD is thought to induce its prototypical psychedelic effects primarily via stimulation of the 5-HT2A receptor. This study investigates whether an LSD experience can be attenuated and shortened using 5-HT2A receptor antagonist ketanserin administration after LSD once the psychedelic effects have established.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

LSD

Keywords

Healthy
View on registry

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.

This study's objects

Directly linked records, matched by DOI, trial reference, or registry, not just topic.

Publications from this trial

ArticleLSD

Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants.

Becker AM, Klaiber A, Holze F +5

Europe PMC2023

Related research

ArticlePsilocybin

MFCC-DFT mapping of ligand recognition at the 5-HT<sub>2A</sub> receptor: energetic analysis of the interactions between serotonin, psychedelics, and antipsychotics.

Junior WSC, Bezerra KS, Matias EGC +2

Europe PMC2026
ArticleLSD

LSD modulates effective connectivity and neural adaptation mechanisms in an auditory oddball paradigm.

Timmermann C, Spriggs MJ, Kaelen M +5

Europe PMC2018
ArticleLSD

Phospholipase C mediates (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-, but not lysergic acid diethylamide (LSD)-elicited head bobs in rabbit medial prefrontal cortex.

Schindler EA, Harvey JA, Aloyo VJ

Europe PMC2013